menu
    • menu

    Company profile for TrippBio

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    TrippBio is a new biotechnology company dedicated to the discovery of treatments for infectious diseases with a specialization in emerging respiratory viruses. TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to prevent and treat rogue viruses, like SARS-CoV-2, the virus that causes COVID-19. One such drug is currently in an advanced phase of testing, TD213. This drug is...
    TrippBio is a new biotechnology company dedicated to the discovery of treatments for infectious diseases with a specialization in emerging respiratory viruses. TrippBio focuses on developing innovative applications of existing drugs with low risk and high efficacy to prevent and treat rogue viruses, like SARS-CoV-2, the virus that causes COVID-19. One such drug is currently in an advanced phase of testing, TD213. This drug is showing great potential and if proven successful, could be a unique mechanism of action to help millions. And this is where you come in.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    TrippBioUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    10752 Deerwood Park Blvd, Suite 100 Jacksonville, FL 32256
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://trippbio.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    TrippBio Announces Agreement with NIAID to Evaluate PanCytoVirâ„¢
    TrippBio Announces Agreement with NIAID to Evaluate PanCytoVir™

    13 Sep 2022

    // APNEWS

    https://apnews.com/article/science-health-covid-florida-c5ebc6287a309fadbd029ec6eff95824

    APNEWS
    13 Sep 2022
    Share Share
    TrippBio announces publication data supporting the antiviral potency of TD-213
    TrippBio announces publication data supporting the antiviral potency of TD-213

    26 May 2021

    // PRWEB

    https://www.prweb.com/releases/trippbio_announces_publication_of_data_supporting_the_antiviral_potency_of_td_213_against_sars_cov_2/prweb17959686.htm

    PRWEB
    26 May 2021
    Share Share
    TrippBio Reports Positive Results from Investigator-Initiated Trial of TD213
    TrippBio Reports Positive Results from Investigator-Initiated Trial of TD213

    16 Nov 2020

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/trippbio-reports-positive-results-from-investigator-initiated-clinical-trial-of-td213-for-the-treatment-of-mild-to-moderate-covid-19-infections-301173964.html

    PRNEWSWIRE
    16 Nov 2020
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search